exv99w1 AMERICAN SHARED HOSPITAL SERVICES ORDERS FOUR LEKSELL GAMMA KNIFE PERFEXION SYSTEMS FOR CLINICAL PARTNER SITE UPGRADES San Francisco, CA

AMERICAN SHARED HOSPITAL SERVICES

ORDERS FOUR LEKSELL GAMMA KNIFE PERFEXION SYSTEMS

FOR CLINICAL PARTNER SITE UPGRADES

San Francisco, CA, November 6, 2006 AMERICAN SHARED HOSPITAL SERVICES (AMEX,PCX:AMS), a leading

provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services,

announced today that it has ordered four Leksell Gamma Knife Perfexion systems from Elekta AB

(Stockholm Stock Exchange:EKTAb) for planned upgrades of AMS clinical partner sites in the United

Our decision to purchase these advanced new systems is the latest example of AMS commitment to

offering our clinical partners today s most advanced radiosurgery and radiation therapy technology

solutions to improve patient outcomes, said Ernest A. Bates, M.D., Chairman and Chief Executive

Officer of AMS. Leksell Gamma Knife Perfexion expands the Gamma Knife product line with a

completely new system that takes stereotactic radiosurgery to the next level, and provides a

platform for further refinement and expansion of radiosurgery procedures in the brain, skull,

cervical spine and head neck regions. Dr. Bates said that delivery of these new systems is

expected to begin in the spring of 2007.

Tomas Puusepp, President and Chief Executive Officer of Elekta, said, We are pleased to further

develop our collaboration with AMS by delivering these four units to AMS customers, who will be

among the very first in the world to have Leksell Gamma Knife Perfexion installed. Initial reports

suggest that Leksell Gamma Knife Perfexion will support increased patient volumes while at the same

time improving efficiency and saving physician time.

Mr. Puusepp noted that the first patients were successfully treated with Leksell Gamma Knife

Perfexion in July at H spital la Timone (Timone University Hospital) in Marseille, France. In a

report on the first 30 patients presented at the Congress of Neurological Surgeons (CNS) annual

meeting in Chicago this past October, the team in Marseille said, In this preliminary experience

Leksell Gamma Knife Perfexion is turning out to represent a great improvement other radiosurgical

technologies and even over earlier Gamma Knife systems. Our overall feeling is that this new

generation platform for radiosurgery is a real quantum leap for radiosurgery technology and appears

to makes radiosurgery even easier, faster and safer than before.

Leksell Gamma Knife Perfexion

Leksell Gamma Knife Perfexion maintains full clinical compatibility with the classic Leksell Gamma

Knife and is supported by efficacy and outcome data from 400,000 treated patients worldwide and

thousands of peer-reviewed scientific articles, making it a proven choice for radiosurgery of the

brain. According to Elekta, Leksell Gamma Knife Perfexion reduces unwanted body dose to the

patient by up to 100 times compared with competing technologies, which is particularly important

for treatment of children and women of childbearing age, and allows for a dramatically increased

treatable volume, which is estimated to increase the number of patients that can benefit from Gamma

Knife surgery by up to 40 percent. Elekta estimates that the fully automated and efficient single

push-button approach can save 3-5 working weeks of physician time per year at an average Gamma

Elekta is an international medical-technology group providing meaningful clinical solutions,

comprehensive information systems and services for improved cancer care and management of brain

disorders. All of Elekta s solutions employ non-invasive or minimally invasive techniques and are

therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife for non-invasive treatment

of brain disorders and Elekta Synergy for image guided radiation therapy (IGRT).

Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the

world s largest supplier of oncology software.

Elekta s systems and solutions are used at over 4,000 hospitals around the world to treat cancer

and manage clinical operations as well as to diagnose and treat brain disorders, including tumors,

vascular malformations and functional disorders.

With approximately 2,000 employees, Elekta s corporate headquarter is located in Stockholm, Sweden.

For more information about Elekta, please visit www.elekta.com.

American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical

and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery

services, a non-invasive treatment for malignant and benign brain tumors, vascular malformations

and trigeminal neuralgia (facial pain). The Company also offers the latest IGRT and IMRT systems,

as well as its proprietary Operating Room for the 21st Century (OR21 ) concept. Through its equity

investment in Still River Systems, AMS also plans to complement these services with the

Clinatron-250 proton beam radiation therapy (PBRT) system, which has not yet been approved by the

FDA. For more information about AMS, please visit www.ashs.com.

This press release may be deemed to contain certain forward-looking statements with respect to the

financial condition, results of operations and future plans of American Shared Hospital Services,

which involve risks and uncertainties including, but not limited to, the risks of the Gamma Knife

business, the risks of developing its IMRT and The Operating Room for the 21st Century

programs, and the risks of investing in a development-stage company, Still River Systems, Inc.,

without a proven product. Further information on potential factors that could affect the financial

condition, results of operations and future plans of American Shared Hospital Services is included

in the filings of the Company with the Securities and Exchange Commission, including the Company s

Annual Report on Form 10-K for the year ended December 31, 2005, the Form 10-Q for the three months

ended March 31, 2006 and June 30, 2006, and the definitive Proxy Statement for the Annual Meeting

of Shareholders on June 28, 2006.